Typical clinical uses
- Clinical chemistry, hematology, and immunoassay analyzers
- Molecular diagnostics and PCR platforms
- Point-of-care IVD devices (POC)
- Companion diagnostics tied to therapeutics
- LIS / LIMS middleware and lab-automation orchestration
MedTech segment · IVD
In-Vitro Diagnostics (IVD) cybersecurity.
Cybersecurity for IVD analyzers, LIS integrations, and lab platforms.
What we mean by ivd.
IVD analyzers are connected lab instruments that integrate with LIS, middleware, and increasingly cloud reporting. We secure the LIS interface, instrument OS, and remote service paths against both unauthenticated network attacks and insider misuse.
Connected IVD analyzers and middleware sit between lab samples, LIS systems, and increasingly the cloud. A result-tampering compromise is a direct patient-safety event, and lab protocols (HL7, ASTM) often have no native authentication - the design must compensate at the network and middleware layers.
Cloud connectivity changes the risk class of a previously offline IVD for both FDA and customers - it is not just a back-end change.
Key data flows & integrations
- Analyzer ↔ middleware (HL7, ASTM, vendor protocols)
- Middleware ↔ LIS / LIMS
- LIS ↔ EHR (HL7, FHIR)
- Analyzer ↔ vendor remote-service tunnel
- Analyzer / cloud ↔ reagent / cartridge identity service
Threat surface
Cyber risks specific to ivd.
LIS / ASTM / HL7 parser hardening
Lab interface parsers are a chronic source of memory-safety and authorization bugs.
Embedded Windows / Linux exposure
Many analyzers run end-of-life OS images - patching, allowlisting, and segmentation must be documented.
Service-engineer remote access
Vendor remote support paths must be MFA-protected and session-logged.
Top concerns
Top cybersecurity concerns for ivd.
Connected IVD analyzers and middleware sit between lab samples, LIS systems, and (increasingly) the cloud - a result-tampering compromise is a direct patient-safety event.
- Result integrity from analyzer → LIS → EHR
- Middleware exposure and weak service-account isolation
- Software supply-chain risk in vendor middleware
- Remote-service tools used by field engineers
- Lab network segmentation and HL7/ASTM trust boundaries
- PHI exposure in analyzer logs and diagnostic dumps
- Cloud LIS / cloud-LIMS multi-tenant separation
- Reagent / cartridge identity authentication
Operational challenges
Where ivd teams get stuck.
HL7 / ASTM implicit trust
Lab protocols often have no native authentication - your design must compensate at the network and middleware layers.
Vendor remote service
Service-engineer tooling is a recurring entry point and must be treated as a production interface in the threat model.
Cloud-connected analyzers
Adding cloud connectivity to a previously offline IVD changes its risk class for both FDA and customers.
Multi-jurisdictional data flows
Cross-border lab networks bring GDPR, HIPAA, and local data-residency obligations into your cloud architecture.
What FDA scrutinizes
Reviewer focus areas
Result integrity end-to-end
Reviewers want explicit modeling of analyzer → LIS → EHR with integrity controls at each hop.
Cloud-connected reclassification
Adding cloud changes the risk profile and the cyber documentation expected.
Reagent / cartridge authentication
Counterfeit and tampered consumables are an emerging concern - identity authentication should be in the threat model.
Regulatory pathways and standards
Regulatory pathways
FDA pathways we support
510(k) De Novo PMA
Standards & guidance
Applicable standards
FDA 2026 Premarket Cyber Guidance AAMI SW96 IEC 62304 CLIA ISO 15189
Services
How we help ivd teams.
FAQs
IVD cybersecurity FAQs.
Do CLIA labs change cyber expectations?
CLIA is operational; FDA cyber expectations apply to the IVD as a regulated device. Both apply in parallel.
How do you handle analyzers running end-of-life Windows?
We document compensating controls (segmentation, allowlisting, restricted services) in the SPDF and labeling, and we test the resulting attack surface from both authenticated and unauthenticated positions.
What about LIS / ASTM / HL7 interface testing?
We fuzz the parsers, test authentication and authorization on every message type in scope, and verify behavior under malformed and oversized payloads.
Do you cover service-engineer remote access?
Yes - vendor remote support paths get a dedicated review: MFA, jump-host isolation, full session logging, and least-privilege scoping. Often a high-value finding area.
How is middleware in scope?
If you ship or recommend middleware as part of the cleared system, it's in scope. We test it the same way as the analyzer - appsec, authentication, integration security.
What's the postmarket expectation for IVDs?
SBOM monitoring on the analyzer OS and middleware, a CVD program, and a documented patch/update plan that respects clinical-lab uptime constraints.
IVD cybersecurity
Get IVD-specific cybersecurity documentation, not generic boilerplate.
LIS/HL7 interface testing, instrument firmware review, and SBOM for IVD analyzers and molecular platforms.
- 30-min discovery call
- Fixed-fee proposal in 48 hrs
- No sales pressure
Other segments
Explore more MedTech segments
In their words
Backed by MedTech leaders.
HT
"Blue Goat Cyber's depth of expertise was impressive. We had no in-house cybersecurity experience, and their team guided us through every step of the FDA process. The penetration testing and SBOM testing were thorough and gave us complete confidence."
Hank Tucker
CEO · MedTech Manufacturer
For IVD
Get IVD cybersecurity that lands.
Cybersecurity for IVD analyzers, LIS integrations, and lab platforms.